Encouraging milestone in the treatment of ...

An encouraging milestone in the treatment-resistant depression somatized the emergence of selective reversible MAOIs III generation attributable to the new chemical class (derivatives of benzamide). Unlike their predecessors, these drugs meet the safety criteria (a favorable outcome in monoperedozirovke) does not require adherence to the diet (their application is not accompanied by cheese reaction) and the period of waiting for a change of antidepressant. Original drug in this series, available for use in our country has become moclobemide (auroriks), the clinical identification of which lasted for 23 years. As studies in this preparation reveal all-new quality. In the course of neurobiological studies have found moclobemide effect on the basic biological amines (the drug inhibits oxidative deamination of the three groups of biogenic amines noradrenergic, 5-hydroxytryptamine (serotonin) and dopamine), hypothetically involved in the pathogenesis of depression and other disorders of the neurotic spectrum. In clinical studies, the effectiveness of moclobemide was found in some psychiatric disorders that occur in patients who are vulnerable to depression (intellectual, cognitive dysfunction in elderly patients, anxiety and panic disorder, social phobia or social neuroses, eating disorders by type of bulimia, migraine syndrome chronic fatigue, etc.). Multicentre studies conducted in Western America, Canada, Australia, South Africa and several European countries (Switzerland, Austria and France) supported by sufficient efficiency moclobemide in the treatment of depression with different structures (dysthymia, melancholia, atypical depression). Sighting study the therapeutic activity of moclobemide in the two polar types of depression, differing on the basis of the predominance of positive or negative affectivity. In the first stage, data were obtained on the effectiveness of the drug in depression with a predominance of negative symptoms, often regarded as atypical symptoms: apathy (indifference), anhedonia (loss of zest for life with unhappiness, inability to have fun) and mental anesthesia (insensitivity to the painful alienation of their mental and / or somatic functions, feeling fenced off, indifference or lack of participation. In recent years, studies conducted in several European centers, revealed the effectiveness of moclobemide with resistant depression positive pole distinguished complex structure and include an alarm in its various manifestations (including agitated form) and somatization symptom (conversion or vegetative). A number of studies highlighted the effectiveness of moclobemide with lingering anxiety somatized depression resistant to treatment by traditional tricyclic antidepressants (amitriptyline, imipramine, clomipramine, desipramine, trimipramin, etc.).